Skip to main content
Top
Published in: Clinical Rheumatology 7/2018

Open Access 01-07-2018 | Original Article

Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis

Authors: M. Gamala, S. P. Linn-Rasker, M. Nix, B. G. F. Heggelman, J. M. van Laar, P. C. M. Pasker-de Jong, J. W. G. Jacobs, R. Klaasen

Published in: Clinical Rheumatology | Issue 7/2018

Login to get access

Abstract

To establish whether dual-energy CT (DECT) is a diagnostic tool, i.e., associated with initiation or discontinuation of a urate lowering drug (ULD). Secondly, to determine whether DECT results (gout deposition y/n) can be predicted by clinical and laboratory variables. Digital medical records of 147 consecutive patients with clinical suspicion of gout were analyzed retrospectively. Clinical data including medication before and after DECT, lab results, and results from diagnostic joint aspiration and DECT were collected. The relationship between DECT results and clinical and laboratory results was evaluated by univariate regression analyses; predictors showing a p < 0.10 were entered in a multivariate logistic regression model with the DECT result as outcome variable. A backward stepwise technique was applied. After the DECT, 104 of these patients had a clinical diagnosis of gout based on the clinical judgment of the rheumatologist, and in 84 of these patients, the diagnosis was confirmed by demonstration of monosodium urate (MSU) crystals in synovial fluid (SF) or by positive DECT. After DECT, the current ULD was modified in 33 (22.4%) of patients; in 29 of them, ULD was started and in 1 it was intensified. Following DECT, the current ULD was stopped in three patients. In the multivariable regression model, cardiovascular disease (OR 3.07, 95% CI 1.26–7.47), disease duration (OR 1.008, 95% CI 1.001–1.016), frequency of attack (OR 1.23, 95% CI 1.07–1.42), and creatinine clearance (OR 2.03, 95% CI 0.91–1.00) were independently associated with positive DECT results. We found that the DECT result increases the confidence of the prescribers in their decision to initiation or discontinuation of urate lowering therapy regimen in of mono- or oligoarthritis. It may be a useful imaging tool for patients who cannot undergo joint aspiration because of contraindications or with difficult to aspirate joints, or those who refuse joint aspiration. We also suggest the use of DECT in cases where a definitive diagnosis cannot be made from signs, symptoms, and MSU analysis alone.
Literature
3.
go back to reference Clarson L, Chandratre P, Hider S, Belcher J, Heneghan C, Roddy E, et al (2013) Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol Clarson L, Chandratre P, Hider S, Belcher J, Heneghan C, Roddy E, et al (2013) Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol
4.
go back to reference Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD (2014) Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink. Ann Rheum Dis Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD (2014) Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink. Ann Rheum Dis
9.
go back to reference Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1312–1324. https://doi.org/10.1136/ard.2006.055269 CrossRefPubMedPubMedCentral Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1312–1324. https://​doi.​org/​10.​1136/​ard.​2006.​055269 CrossRefPubMedPubMedCentral
10.
go back to reference Perez-Ruiz F (2009) Treating to target: a strategy to cure gout. Rheumatology 48(suppl 2):ii9–ii14CrossRefPubMed Perez-Ruiz F (2009) Treating to target: a strategy to cure gout. Rheumatology 48(suppl 2):ii9–ii14CrossRefPubMed
14.
go back to reference Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1301–1311. https://doi.org/10.1136/ard.2006.055251 CrossRefPubMedPubMedCentral Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1301–1311. https://​doi.​org/​10.​1136/​ard.​2006.​055251 CrossRefPubMedPubMedCentral
16.
19.
go back to reference Bongartz T, Glazebrook KN, Kavros SJ, Murthy NS, Merry SP, Franz WB, III, et al. (2014) Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis Bongartz T, Glazebrook KN, Kavros SJ, Murthy NS, Merry SP, Franz WB, III, et al. (2014) Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis
23.
go back to reference Finkenstaedt T, Manoliou A, Toniolo M, Higashigaito K, Andreisek G, Guggenberger R et al (2016) Gouty arthritis: the diagnostic and therapeutic impact of dual-energy CT. Eur Radiol:1–11 Finkenstaedt T, Manoliou A, Toniolo M, Higashigaito K, Andreisek G, Guggenberger R et al (2016) Gouty arthritis: the diagnostic and therapeutic impact of dual-energy CT. Eur Radiol:1–11
24.
go back to reference Taylor WJ, Fransen J, Dalbeth N, Neogi T, Ralph Schumacher H, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire CA, Cavagna L, Lin C, Chou YY, Tausche AK, da Rocha Castelar-Pinheiro G, Janssen M, Chen JH, Slot O, Cimmino M, Uhlig T, Jansen TL (2016) Diagnostic arthrocentesis for suspicion of gout is safe and well tolerated. J Rheumatol 43(1):150–153. https://doi.org/10.3899/jrheum.150684 CrossRefPubMed Taylor WJ, Fransen J, Dalbeth N, Neogi T, Ralph Schumacher H, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire CA, Cavagna L, Lin C, Chou YY, Tausche AK, da Rocha Castelar-Pinheiro G, Janssen M, Chen JH, Slot O, Cimmino M, Uhlig T, Jansen TL (2016) Diagnostic arthrocentesis for suspicion of gout is safe and well tolerated. J Rheumatol 43(1):150–153. https://​doi.​org/​10.​3899/​jrheum.​150684 CrossRefPubMed
Metadata
Title
Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis
Authors
M. Gamala
S. P. Linn-Rasker
M. Nix
B. G. F. Heggelman
J. M. van Laar
P. C. M. Pasker-de Jong
J. W. G. Jacobs
R. Klaasen
Publication date
01-07-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 7/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-3980-y

Other articles of this Issue 7/2018

Clinical Rheumatology 7/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.